

## Anti-TP53 antibody (270-350 C-Term) (STJ94894) STJ94894

## **GENERAL INFORMATION**

 
 Product Type
 Primary antibodies

 Short
 Rabbit polyclonal antibody anti-Cellular Tumor antigen P53 (270-350 C-Term) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence, Immunocytochemistry and ELISA research applications.

 Applications
 WB, IHC-P, IF, ICC, ELISA

 Reactivity
 Human, Mouse, Rat

## **PRODUCT PROPERTIES**

| Clonality<br>Clone ID  | Polyclonal  |  |  |
|------------------------|---|--|--|
| •.•.•                  |   |  |  |
| Concentration          | 1 mg/mL   |  |  |
| Conjugation            | Unconjugated  |  |  |
| Purification           | The antibody was affinity-purified from rabbit anti-serum by affinity-chromatography.         |  |  |
| Dilution               | WB 1:500-1:2000   |  |  |
| Range                  | IHC 1:100-1:300   |  |  |
|                        | IF 1:200-1:1000   |  |  |
|                        | ELISA 1:10000   |  |  |
| Formulation            | PBS, 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.   |  |  |
| Isotype                | lgG   |  |  |
| Storage<br>Instruction | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |  |  |
| instruction            |   |  |  |

## **TARGET INFORMATION**

| Immunogen  | TP53<br>P53_HUMAN<br>The antiserum was produced against synthesized peptide<br>270-350 C-Term  | le derived from human p53 at amino acid range 301-350<br>inds to endogenous Cellular Tumor Antigen P53 at the amino a   | acid region 270- |
|--|--|---|------------------|
| Immunogen  |  |   |                  |
| Sequence   |  |   |                  |
| (kD)<br>1177-<br>85-<br>48-<br>34-                                       | 117<br>85<br>P53 48<br>34  | Human<br><u>1955 gifen 2447</u><br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190-<br>190- |                  |
| 26-  | 26   |   |                  |
| 19-  | 19<br>(kD)   |   |                  |
| Western blot analysis of HepG2<br>Polyclonal Antibody diluted at 1: 1000 | cells using p53<br>Western blot analysis of lysates from HepG2 cells,<br>using p53 Antibody. The lane on the right is blocked<br>with the synthesized peptide. | Western blot analysis of various cells using p53<br>Polycional Antibody diluted at 1: 1000  |                  |

This product is suitable for in-vitro studies under the RESEARCH USE ONLY [RUO] licence. This product must not be used as for diagnostic or other medical purposes. St John's Laboratory Ltd, Knowledge Dock Business Centre, University Way, London, E16 2RD | Tel: 0208 223 3081